AzTrials
AzTrials

Rotator Cuff TearsNCT07781553

Biomarkers to Predict Rotator Cuff Repair Healing on Postoperative MRI

A study testing MRN in people with Rotator Cuff Tears, run by Joseph W. Galvin at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Rotator cuff repair healing is highly variable with healing failure rates ranging from 11 to 94%. To this date, there are no specific biomarkers in shoulder tissues that can be associated with rotator cuff healing after surgery. Read more about this study

Who is it for?
Ages 18 to 99 years
Conditions the study is for
Rotator Cuff Tears
What is being tested?
MRN
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 siteUnited States
Study dates
1 Sep 2026to 30 Aug 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 99 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • age 18-99 years partial or full thickness posterior superior rotator cuff tear that underwent surgical repair and are consented in the Orthopedics Biobank under IRB# 202403832.
  • Exclusion criteria prisoners pregnant patients patients with prior shoulder surgery on the ipsilateral side adhesive capsulitis patients undergoing concomitant distal clavicle resection worker's compensation patients with postoperative complications.

Who cannot join

None listed.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Joseph Galvin, Other, MD contact

3193848378

joseph-galvin@uiowa.edu

Maria F Bozoghlian, MD contact

3196785003

maria-bozoghlian@uiowa.edu

United States1 site, 1 recruiting
  • University of Iowa

    Iowa City, Iowa, 52242

    Joseph Galvin, DO, 3193537091, joseph-galvin@uiowa.edu

    Maria F Bozoghlian, MD, 3196785003, maria-bozoghlian@uiowa.edu

    Recruiting

Other trials in United States

About this study

Official title: Biomarkers to Predict Rotator Cuff Repair Healing

Rotator cuff repair healing is highly variable with healing failure rates ranging from 11 to 94%. To this date, there are no specific biomarkers in shoulder tissues that can be associated with rotator cuff healing after surgery. The purpose of this study is to perform diagnostic imaging study (MRI without contrast), for research purposes, to subjects in the Orthopedics Biobank (IRB#202403832), to identify biomarkers associated with failure of rotator cuff repair healing. We will evaluate biomarkers in synovial fluid and shoulder tissues collected and analyzed as part of the IRB#202403832, and correlate the difference in biomarkers in patients that did and did not have signs of healing in the MRI. Secondarily, we aim to develop a model using demographics, radiographic parameters/MRI measurements and biomarkers to accurately predict rotator cuff repair healing rates at 1-year following surgery.

This will be a study from a population of patients who are enrolled in the Orthopedic biorepository under IRB #202403832.

Patients who underwent a rotator cuff repair will be invited to get an MRI without contrast of their operated shoulder at a period between 6 months to 1 year post-operative.

Read the detailed description

Rotator cuff repair healing is highly variable with healing failure rates ranging from 11 to 94% [11-15]. A number of variables have been identified which influence rotator cuff repair healing rates including: older age (> 70 years old), size of the tear in anterior posterior dimension, level of tendon retraction, muscle quality and fatty infiltration, osteoporosis, smoking, family history of rotator cuff tears, diagnosis of diabetes mellitus, and level of work activity [7,16-26]. However, there is a paucity of literature and investigation into biomarkers significantly associated with rotator cuff repair healing rates. Tashjian et al. investigated 72 patients undergoing arthroscopic rotator cuff repair for a full-thickness posterosuperior tear. Magnetic resonance imaging studies were performed at a minimum of 1 year postoperatively. The authors found that 42% of repairs failed to heal. Multivariate regression analysis showed a significant association between a family history of rotator cuff tears and overall healing failure (P = .036). Additionally, they identified an increased risk for the presence of a rare allele for SNP rs17583842 single-nucleotide polymorphism (SNP) in the estrogen-related receptor beta (ESRRB) gene. This is the first genetic biomarker to be identified as significantly associated with repair healing. Additional authors have evaluated transcriptomics and gene expression differences in rotator cuff tissue collected during surgery between patients who had good outcomes versus those who had a retear. They found that patients who had poor healing outcomes showed greater expression of gene sets related to extracellular matrix production (P < .0001) and cellular biosynthetic pathways (P < .001), while patients who had good healing outcomes showed greater expression of genes associated with the proinflammatory (M1) macrophage phenotype (P < .05). Although this data is interesting, tissue level biomarkers are less useful in the clinical setting as a preoperative prognostic tool. No studies to our knowledge have identified blood transcriptomic or proteomic biomarkers associated with rotator cuff tear healing.

Therefore, we aim to investigate this through this protocol. Numerous studies have identified that the diagnosis of diabetes mellitus type 2 (DM2) is a risk factor for failure of rotator cuff repair healing [28]. Yang et al. conducted a meta-analysis to compare clinical outcomes and retear rates after rotator cuff repair in patients with and without diabetes. Diabetes was associated with a higher retear rate (19.3% in patients without diabetes vs 28.2% in patients with diabetes; P < .0001). The retear rate according to the severity of sustained hyperglycemia in the subgroup analysis was 14.6% in patients without diabetes, versus 22.7% in patients with well-controlled diabetes (<7.0% of preoperative serum HbA1c level; P = .12) and 40% in patients with uncontrolled diabetes (HbA1c level >7.0%; P < .00001). Recently, studies have identified that serum fructosamine, rather than Hemoglobin A1C percentage, is a more accurate marker of acute glycemic control. Shohat et al. evaluated 1119 patients undergoing total knee arthroplasty. They found that patients with high fructosamine (> 293) were 11.2 times more likely to develop prosthetic joint infection compared with patients with low fructosamine (p = 0.001). Another study published in the prestigious Nature Journal by Shohat et al. assessed the utility of serum fructosamine to predict adverse outcomes following total hip arthroplasty (THA) [30]. Patients with elevated fructosamine were also associated with more readmissions (16.7% vs. 4.4%, p < 0.007) and a higher mortality rate (3.7% vs. 0.6%, p = 0.057). We hypothesize that fructosamine level is significantly associated with healing rates following rotator cuff repair and plan to investigate this in a prospective fashion through this protocol.

One of the aims of this study protocol is to develop a model using demographics, radiographic parameters/MRI measurements and biomarkers to accurately predict rotator cuff repair healing rates at 1-year following surgery. Kwon et al. conducted a case-control study of 603 patients who underwent arthroscopic rotator cuff repair and had 1-year follow up with a postoperative MRI. Of the 603 patients, the healing rate was 24%. The following independent risk factors were identified in the multivariate analysis: age > 70 years at the time of surgery (P = .003, Odds Ratio (OR) = 2.71), size of the tear in anterior posterior dimension (P = .033, OR = 1.94), level of tendon retraction (P = .000, OR = 4.56), fatty infiltration of infraspinatus exceeding grade 2 (P = .001, OR = 2.91), low bone mineral density as measured on DEXA scans (T score > -2.5, P = .04, OR = 1.95), and high level of work activity (P = .036, OR = 2.18). They created a 15-point scoring system comprised the following: 4 points for retraction; 3 points for fatty infiltration of infraspinatus; and 2 points for anteroposterior tear size, age, bone mineral density, and work activity. These variables were weighted according to multivariate analysis ORs. Patients with less than or equal to 4 points had a 6.0% healing failure rate, and those with greater than or equal to 5 and greater than or equal to 10 points had 55.2% and 86.2% healing failure rates, respectively. This Rotator Cuff Healing Index (ROHI) score is clinically helpful as it can provide preoperative prognostic information to the surgeon and patient to guide decision making on whether to perform an arthroscopic repair, perform a repair with possible patch augmentation, or potentially guide the decision making to a reverse shoulder arthroplasty. Through this study protocol, we aim to identify current accepted protein biomarkers (fructosamine) and perform discovery proteomics and transcriptomics to identify novel biomarkers associated with rotator cuff repair healing.

Being tested
MRN
Keywords
rotator cuff tear; rotator cuff healing
Medical subject headings
Rotator Cuff Injuries

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MRNDiagnostic test

    MRN without contrast

Study groups in NCT07781553
Study groupRoleWhat they receive
Rotator cuff repairOtherAll participants of the Orthopedics Biobank who underwent a rotator cuff repair will be part of arm 1
Receives: Diagnostic Test: MRN

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Rotator cuff healing

    Rotator cuff healing postoperatively, as assessed on MRI

    Measured: 6 months to 1 year post-operative

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Aug 2026
  2. Study start1 Sep 2026 (estimated)
  3. Primary completion30 Jul 2027 (estimated)
  4. Study completion30 Aug 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07781553
Sponsor's protocol ID
202406235
Status last verified
Aug 2026
First submitted
18 Aug 2026
Last updated
24 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing MRN in people with Rotator Cuff Tears, run by Joseph W. Galvin at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 24 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Joseph Galvin, Other, MD (3193848378, joseph-galvin@uiowa.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Rotator cuff healing (time frame: 6 months to 1 year post-operative). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in